Jiyeon Kim, PhD
Assistant Professor of Urology and Cellular & Molecular PhysiologyCards
Appointments
Contact Info
Yale School of Medicine
310 Cedar St., BML
New Haven, Connecticut 06519
United States
About
Titles
Assistant Professor of Urology and Cellular & Molecular Physiology
Biography
Dr. Kim is a basic research scientist in the Department of Urology with a joint appointment in the Department of Cellular and Molecular Physiology. She received her PhD from the Department of Molecular Cancer Biology at Duke University under the supervision of Dr. Sally Kornbluth, and her postdoctoral training from Dr. Ralph DeBerardinis at UT-Southwestern Medical Center. Before coming to Yale, she was The Kim lab is focused on understanding how metabolic alterations elicit dependencies and liabilities in certain signaling pathways and how we can target the pathway as cancer’s Achilles' heel.
The lab has been actively applying metabolic flux analysis to panels of cancer cell lines with various mutations to understand the full breadth of metabolic diversity in cancer. These studies are complemented by in vivo analyses of cancer metabolism in mice, and by translational efforts designed to understand and exploit the metabolic idiosyncrasies of tumor cells.
Appointments
Urology
Assistant ProfessorPrimaryCellular & Molecular Physiology
Assistant ProfessorSecondary
Other Departments & Organizations
Education & Training
- Postdoctoral fellow
- UT-Southwestern Medical Center (2018)
- PhD
- Duke University, Molecular Cancer Biology (2012)
Research
Research at a Glance
Publications Timeline
Publications
2022
A new role for ammonia in tumorigenesis?
Lee HM, Nayak A, Kim J. A new role for ammonia in tumorigenesis? Cell Metab 2022, 34: 944-946. PMID: 35793658, DOI: 10.1016/j.cmet.2022.06.009.Commentaries, Editorials and LettersTargeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer.
Lee H, Cai F, Kelekar N, Velupally NK, Kim J. Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer. Cells 2022, 11 PMID: 35011738, DOI: 10.3390/cells11010176.Peer-Reviewed Original Research
2020
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu EL, Muhammad N, Rhyne S, Li K, Haloul M, Gu W, Faubert B, Kaushik AK, Cai L, Kasiri S, Marriam U, Nham K, Girard L, Wang H, Sun X, Kim J, Minna JD, Unsal-Kacmaz K, DeBerardinis RJ. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab 2020, 2: 1401-1412. PMID: 33257855, DOI: 10.1038/s42255-020-00316-0.Peer-Reviewed Original ResearchAmino acids in cancer.
Lieu EL, Nguyen T, Rhyne S, Kim J. Amino acids in cancer. Exp Mol Med 2020, 52: 15-30. PMID: 31980738, DOI: 10.1038/s12276-020-0375-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2019
Mechanisms and Implications of Metabolic Heterogeneity in Cancer.
Kim J, DeBerardinis RJ. Mechanisms and Implications of Metabolic Heterogeneity in Cancer. Cell Metab 2019, 30: 434-446. PMID: 31484055, DOI: 10.1016/j.cmet.2019.08.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2017
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B, Bezwada D, Rodriguez-Canales J, Villalobos P, Lin YF, Ni M, Huffman KE, Girard L, Byers LA, Unsal-Kacmaz K, Peña CG, Heymach JV, Wauters E, Vansteenkiste J, Castrillon DH, Chen BPC, Wistuba I, Lambrechts D, Xu J, Minna JD, DeBerardinis RJ. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature 2017, 546: 168-172. PMID: 28538732, DOI: 10.1038/nature22359.Peer-Reviewed Original Research
2016
Blocking fatty acid synthesis reduces lung tumor growth in mice.
Kim J, DeBerardinis RJ. Blocking fatty acid synthesis reduces lung tumor growth in mice. Nat Med 2016, 22: 1077-1078. PMID: 27711061, DOI: 10.1038/nm.4195.Commentaries, Editorials and Letters
2013
Cancer. Silencing a metabolic oncogene.
Kim J, DeBerardinis RJ. Cancer. Silencing a metabolic oncogene. Science 2013, 340: 558-9. PMID: 23641103, DOI: 10.1126/science.1238523.Commentaries, Editorials and Letters
2012
Rsk-mediated phosphorylation and 14-3-3ɛ binding of Apaf-1 suppresses cytochrome c-induced apoptosis.
Kim J, Parrish AB, Kurokawa M, Matsuura K, Freel CD, Andersen JL, Johnson CE, Kornbluth S. Rsk-mediated phosphorylation and 14-3-3ɛ binding of Apaf-1 suppresses cytochrome c-induced apoptosis. EMBO J 2012, 31: 1279-92. PMID: 22246185, DOI: 10.1038/emboj.2011.491.Peer-Reviewed Original Research
2009
Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
Chi XZ, Kim J, Lee YH, Lee JW, Lee KS, Wee H, Kim WJ, Park WY, Oh BC, Stein GS, Ito Y, van Wijnen AJ, Bae SC. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res 2009, 69: 8111-9. PMID: 19808967, DOI: 10.1158/0008-5472.CAN-09-1057.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
honor Innovation Award
National AwardAmerican Lung AssociationDetails02/01/2022United Stateshonor Research Scholar Grant
National AwardAmerican Cancer SocietyDetails01/01/2022United Stateshonor V Scholar Award
National AwardV FoundationDetails07/01/2020United Stateshonor K22 Transition Career Development Award
National AwardNational Cancer InstituteDetails04/01/2019United Stateshonor Cancer Discovery Award
National AwardAmerican Lung AssociationDetails01/01/2019United States
News
News
- July 31, 2024
Yale Urology Research [Q2: April-June 2024]
- June 24, 2024
2024 Yale Urology Graduation Awards
- May 24, 2024
The "Why" for Yale Urology Research Faculty
- January 19, 2024
Yale Urology Research [Q4: October-December 2023]
Get In Touch
Contacts
Yale School of Medicine
310 Cedar St., BML
New Haven, Connecticut 06519
United States
Locations
Brady Memorial Laboratory
Lab
310 Cedar Street, Fl 2, Rm 246
New Haven, CT 06510
General Information
203.737.6295